Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06590961 · ClinicalTrials.gov registry record · Phase 1
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
A Phase 1 study of Relapsed/Refractory B-cell Malignancies, sponsored by Ubix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 11
- Study locations
NCT06590961: Recruiting Phase 1 study of Relapsed/Refractory B-cell Malignancies, sponsored by Ubix Therapeutics.
NCT06590961 is a Phase 1 study of Relapsed/Refractory B-cell Malignancies that is actively recruiting participants, run by Ubix Therapeutics. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06590961, a Phase 1 study of Relapsed/Refractory B-cell Malignancies, is actively recruiting participants, sponsored by Ubix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Primary Outcome
Phase 1a and 1b
Conditions Studied
Interventions
- DRUG UBX-303061
Study Locations (11)
Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- The Catholic University of Korea, Seoul St. Mary's Hospital - Seoul
- The Catholic University of Korea, Yeouido St. Mary's Hospital - Seoul
Michigan
- University of Michigan - Ann Arbor
Oklahoma
- Gabrail Cancer Center - Canton
Texas
- MD Anderson Cancer Center - Houston
Kuyavian-Pomeranian Voivodeship
- MICS Centrum Medyczne Toruń - Torun
Mazowieckie Voivodeship
- Pratia, MTZ Clinical Research - Warsaw
Silesian Voivodeship
- Pratia, Oncology Katowice - Katowice
Wielkopolskie Voivodeship
- AidPort - Grodzisk Wielkopolski
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2025-02-20 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT06590961 shows while recruiting
NCT06590961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Relapsed/Refractory B-cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which UBX-303061 is the first listed.
NCT06590961 lists 11 locations in 8 states (Seoul, Michigan, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT06590961 about?
NCT06590961 is a clinical study titled "UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies". This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
What is the current status of trial NCT06590961?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2025-02-20. Estimated completion is 2027-08.
What conditions does trial NCT06590961 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-cell Malignancies.
What interventions are being tested in trial NCT06590961?
The interventions under investigation include: UBX-303061 (DRUG).
Who is sponsoring clinical trial NCT06590961?
This trial is sponsored by Ubix Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06590961 being conducted?
This trial has 11 study locations across Michigan, Oklahoma, Texas, Kuyavian-Pomeranian Voivodeship, Mazowieckie Voivodeship. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06590961's enrollment target sits among peer trials
94 616th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI